Mektix Chewable 2.5 mg/25 mg Film-coated Tablets for Small Dogs and Puppies Weighing at Least 0.5 kg

Parasite resistance to any particular class of anthelmintic may develop following
frequent, repeated use of an anthelmintic of that class.
It is recommended to treat all the animals in the same household concomitantly.
In order to develop an effective worm control programme local epidemiological
information and the risk of exposure of the dog should be taken into account,
and it is recommended to seek professional (e. g. veterinary) advice.
When D. caninum infection is present, concomitant treatment against
intermediate hosts, such as fleas and lice, should be considered to prevent re-
infection.

Parasite resistance to any particular class of anthelmintic may develop following
frequent, repeated use of an anthelmintic of that class.
It is recommended to treat all the animals in the same household concomitantly.
In order to develop an effective worm control programme local epidemiological
information and the risk of exposure of the dog should be taken into account,
and it is recommended to seek professional (e. g. veterinary) advice.
When D. caninum infection is present, concomitant treatment against
intermediate hosts, such as fleas and lice, should be considered to prevent re-
infection.
4.5 Special precautions for use
Special precautions for use in animals
Studies with milbemycin oxime indicate that the margin of safety in certain dogs
of Collie or related breeds is less than in other breeds. In these dogs, the
recommended dose should be strictly observed.
The tolerance of the veterinary medicinal product in young puppies from these
breeds has not been investigated.
Clinical signs in Collies are similar to those seen in the general dog population
when overdosed.
Treatment of dogs with a high number of circulating microfilariae can sometimes
lead to the appearance of hypersensitivity reactions, such as pale mucous
membranes, vomiting, trembling, laboured breathing or excessive salivation.
These reactions are associated with the release of proteins from dead or dying
microfilariae and are not a direct toxic effect of the veterinary medicinal product.
The use in dogs suffering from microfilaremia is thus not recommended.
In heartworm risk-areas, or in the case it is known that a dog has been travelling
to and from heartworm risk regions, before using the veterinary medicinal

Revised: August 2023
AN: 02617/2022
product, a veterinary consultation is advised to exclude the presence of any
concurrent infestation of Dirofilaria immitis. In the case of a positive diagnosis,
adulticidal therapy is indicated before administering the veterinary medicinal
product.
No studies have been performed with severely debilitated dogs or individuals
with seriously compromised kidney or liver function. The veterinary medicinal
product is not recommended for such animals or only according to a benefit/risk
assessment by the responsible veterinarian.
In dogs less than 4 weeks old, tapeworm infection is unusual. Treatment of
animals less than 4 weeks old with a combination veterinary medicinal product
may therefore not be necessary.
As the tablets are flavoured, they should be stored in a safe place out of the
reach of animals.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
Accidental ingestion of a tablet by a child may be harmful. In order to prevent
children from accessing the veterinary medicinal product, tablets should be
administered and stored out of sight and reach of children.
Part tablets should be returned to the open blister pocket and inserted into the
outer carton.
In the event of accidental ingestion of one or more tablets, seek medical advice
immediately and show the package leaflet or the label to the doctor.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.
Other precautions
Echinococcosis represents a hazard for humans. As Echinococcosis is a
notifiable disease to the World Organisation for Animal Health (OIE), specific
guidelines on the treatment and follow-up, and on the safeguard of persons,
need to be obtained from the relevant competent authority (e. g. experts or
institutes of parasitology).